{"created":"2023-06-19T10:21:48.464711+00:00","id":776,"links":{},"metadata":{"_buckets":{"deposit":"21cb9107-9994-446c-b8da-7ca1a64d203e"},"_deposit":{"created_by":12,"id":"776","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"776"},"status":"published"},"_oai":{"id":"oai:saitama-med.repo.nii.ac.jp:00000776","sets":["9:7:125"]},"author_link":["2581","2579","2584","2583","2582","2585","2586","2580"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"10","bibliographicPageStart":"1","bibliographicVolumeNumber":"47","bibliographic_titles":[{"bibliographic_title":"埼玉医科大学雑誌"},{"bibliographic_title":"Journal of  Saitama Medical University ","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"背景:頻回再発型およびステロイド依存性ネフローゼ症候群に対し,小児では寛解維持・再発抑制におけるリツキシマブ(RTX)の有効性が様々な臨床研究によって実証されている.一方,成人例での実績報告は少なく,また投与プロトコールについても確立された方法がない.そこで今回,成人の頻回再発型およびステロイド依存性ネフローゼ症候群に対する,統一投与プロトコールによるRTXの有用性と安全性を検討した.方法:16歳以上の頻回再発型およびステロイド依存性ネフローゼ症候群に対し,RTX 375mg/m2(最大500mg)単回投与を6ヵ月毎に行い,24ヵ月で計5回投与するプロトコールを採用した.RTX導入前,投与期間中ならびに終了後の臨床経過を観察し,比較検討した.結果:症例は男性9例,女性8例の17例(平均年齢37±15歳:微小変化群11例,巣状糸球体硬化症2例,腎生検未施行4例).観察期間は中央値43ヵ月(11-54ヵ月)であった.RTX投与期間中,ネフローゼ症候群が再発した症例は3例であった.副腎皮質ステロイド薬(プレドニゾロン)とシクロスポリンについては,両者ともRTX導入前とRTX投与期間中および後で投与量が有意に減量されていた.再発回数についても,RTX導入前と比べて,投与期間中および後で有意に減少していた.また,全例で有意な有害事象は認められなかった.結語:成人の頻回再発型およびステロイド依存性ネフローゼ症候群に対し,RTX単回投与を6ヵ月毎に,24ヵ月間で計5回投与するプロトコールは,副腎皮質ステロイド薬・免疫抑制薬の減量や再発抑制において有用性が認められた.(著者抄録)\n\nBackground: A number of clinical trials have demonstrated the effectiveness of Rituximab（RTX）on maintaining remission and suppressing relapse in children with frequent relapse and/or steroid-dependent nephrotic syndrome（FR and/or SDNS）. On the other hand, there are few reports of the results in adult cases, and there is no established protocol for the administration. In this study, we investigated the clinical usefulness and safety of RTX for FR and/or SDNS in adults. Methods: RTX at 375 mg/m2（maximum 500 mg）is administered once every 6 months for adult patients with FR and/or SDNS over 16 years of age, for a total of 5 doses during 24 months, as the RTX treatment protocol. The clinical course before（at least 2 years）, during and after RTX treatment period was observed and analyzed. Results: Seventeen patients consisting of 9 males and 8 females（mean age 37 ± 15 years old）were employed. Among them, 11 cases were with minimal change nephrotic syndrome, 2 cases with focal and segmental glomerulosclerosis, and 4 cases with unknown causes. The median of observation period was 43 months（11-54 months）. Among them, 14 patients finished receiving 5 times RTX treatments for 2 years. There were 3 cases with relapse during RTX treatment period. Both of the doses of corticosteroid（prednisolone）and cyclosporine before RTX treatment was significantly lowered during RTX treatment period. The frequencies of relapse before RTX treatment were also significantly reduced during and after RTX treatment period. In all cases, no significant adverse events were observed. Conclusion: In this study, the protocol of RTX administration at a single dose every 6 months for 24 months（a total of 5 doses）was found to be useful on suppressing relapse and lowering the corticosteroid dose in adult patients with FR and/or SDNS.","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"埼玉医科大学医学会"}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"埼玉医科大学雑誌"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.saitama-med.ac.jp/jsms/vol47/jsms47_001-010.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN0009506X","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0385-5074","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_24":{"attribute_name":"記事区分","attribute_value_mlt":[{"subitem_text_value":"原著 / original"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"瀬戸, 建"},{"creatorName":"セト, タケル","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2579","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"井上, 勉"},{"creatorName":"イノウエ, ツトム","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2580","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"友利, 浩司"},{"creatorName":"トモリ, コウジ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2581","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡田, 浩一"},{"creatorName":"オカダ, ヒロカズ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"2582","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Seto, Takeru","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2583","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Inoue, Tsutomu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2584","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tomori, Kouji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2585","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okada, Hirokazu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2586","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-10-28"}],"displaytype":"detail","filename":"jsms47_1_001-010.pdf","filesize":[{"value":"1.9 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"埼玉医科大学雑誌47巻1号1-10頁","url":"https://saitama-med.repo.nii.ac.jp/record/776/files/jsms47_1_001-010.pdf"},"version_id":"c3943153-8396-4ae3-8e24-5afedf39db42"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Ciclosporin(治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"ネフローゼ-リポイド(薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"*ネフローゼ症候群(薬物療法,予防)","subitem_subject_scheme":"Other"},{"subitem_subject":"Prednisolone(治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"再発","subitem_subject_scheme":"Other"},{"subitem_subject":"糸球体硬化症-巣状分節性(薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"投薬計画","subitem_subject_scheme":"Other"},{"subitem_subject":"臨床試験","subitem_subject_scheme":"Other"},{"subitem_subject":"CD19抗原","subitem_subject_scheme":"Other"},{"subitem_subject":"CD20抗原","subitem_subject_scheme":"Other"},{"subitem_subject":"治療成績","subitem_subject_scheme":"Other"},{"subitem_subject":"*Rituximab(治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"二次予防","subitem_subject_scheme":"Other"},{"subitem_subject":"ヒト","subitem_subject_scheme":"Other"},{"subitem_subject":"青年期(13〜18)","subitem_subject_scheme":"Other"},{"subitem_subject":"成人(19〜44)","subitem_subject_scheme":"Other"},{"subitem_subject":"中年(45〜64)","subitem_subject_scheme":"Other"},{"subitem_subject":"男","subitem_subject_scheme":"Other"},{"subitem_subject":"女","subitem_subject_scheme":"Other"},{"subitem_subject":"frequent relapse nephrotic syndrome","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"steroid-dependent nephrotic syndrome","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"rituximab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"rednisolone","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"cyclosporin A","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"relapse","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"成人頻回再発型およびステロイド依存性ネフローゼ症候群に対するリツキシマブの寛解維持および再発予防効果の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"成人頻回再発型およびステロイド依存性ネフローゼ症候群に対するリツキシマブの寛解維持および再発予防効果の検討"},{"subitem_title":"Effects of long-term treatment with Rituximab on remission maintenance and relapse suppression of frequent relapse and/or steroid-dependent nephrotic syndrome in adults","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"12","path":["125"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-10-28"},"publish_date":"2021-10-28","publish_status":"0","recid":"776","relation_version_is_last":true,"title":["成人頻回再発型およびステロイド依存性ネフローゼ症候群に対するリツキシマブの寛解維持および再発予防効果の検討"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2023-06-19T10:29:45.497844+00:00"}